|premium|

BBBY Stock Forecast: Bed Bath & Beyond plummets as AMC, GameStop continue to sink

  • NASDAQ:BBBY fell by 16.23% during Monday’s trading session.
  • The aftermath of Ryan Cohen selling his stake in BBBY is not a pretty one.
  • AMC begins listing its preferred shares that are trading under the ticker symbol APE.

NASDAQ:BBBY has seen its improbably short squeeze run come to an end and many retail traders have been left holding the bag. On Monday, shares of BBBY tumbled by a further 16.23% and closed the trading session at a price of $9.24. Stocks pulled way back on Monday, erasing much of the recent summer rally. Investors seem apprehensive ahead of the Fed’s key Jackson Hole Symposium that will be held later this week. Overall, the Dow Jones tumbled by 643 basis points, while the S&P 500 and the NASDAQ slumped by 2.14% and 2.55% respectively during what was the worst trading day for stocks since June.


Stay up to speed with hot stocks' news!


The surprisingly abrupt end to the Bed Bath and Beyond meme stock is still resonating with meme stock traders. GameStop (NYSE:GME) Chairman Ryan Cohen sold his stake and all of his call options in the midst of a short squeeze, and took most of the profits. This obviously didn’t sit well with most traders, many of whom are still left holding the bag of a business that certainly does not have a favorable future. Almost all of the gains made from the short squeeze for BBBY have now been lost.

BBBY stock price

BBBY Stock

In other meme stock news, AMC (NYSE:AMC) debuted its controversial preferred shares that are trading under the ticker symbol NYSE:APE. While many Apes believed that this would save the stock, others saw the underlying dilution that this would cause. Shares of AMC tumbled by 41.92% and APE shares fell by 13.67% during its first day of trading.


Like this article? Help us with some feedback by answering this survey:

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to PremiumSign In

Author

More from Stocks Reporter
Share:

Editor's Picks

EUR/USD retakes 1.1800 on renewed USD weakness

EUR/USD gains ground after three days of losses, re-attempting 1.1800in the European trading hours on Thursday. The US Dollar sees fresh selling interest across the board, despite hawkish Fed Minutes, as the market mood improves and supports the pair. US Jobless Claims data, Fedspeak and geopolitics remain in focus. 

GBP/USD recovers above 1.3500 amid better mood

GBP/USD finds fresh demand and rises back above 1.3500 in the European session on Thursday. Improving risk sentiment and renewed US Dollar weakness are helping the pair recover ground ahead of mid-tier US data releases and Fedspeak. 

Gold clings to gains above $5,000 amid safe-haven flows and Fed rate cut bets

Gold sticks to modest intraday gains, above the $5,000 psychological mark, through the first half of the European session, though it lacks bullish conviction amid mixed cues. The third round of US-mediated negotiations between Ukraine and Russia concluded in Geneva on Wednesday without any major breakthrough.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments. The technical outlook suggests further gains if INJ breaks above key resistance.

Hawkish Fed minutes and a market finding its footing

It was green across the board for US Stock market indexes at the close on Wednesday, with most S&P 500 names ending higher, adding 38 points (0.6%) to 6,881 overall. At the GICS sector level, energy led gains, followed by technology and consumer discretionary, while utilities and real estate posted the largest losses.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments.